These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 27772698)

  • 1. Comparison of Ambulatory, High-Dose, Intravenous Diuretic Therapy to Standard Hospitalization and Diuretic Therapy for Treatment of Acute Decompensated Heart Failure.
    Buckley LF; Seoane-Vazquez E; Cheng JW; Aldemerdash A; Cooper IM; Matta L; Medina DS; Mehra MR; Navarro-Velez K; Shea EL; Weintraub JR; Stevenson LW; Desai AS
    Am J Cardiol; 2016 Nov; 118(9):1350-1355. PubMed ID: 27772698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit.
    Buckley LF; Carter DM; Matta L; Cheng JW; Stevens C; Belenkiy RM; Burpee LJ; Young MA; Weiffenbach CS; Smallwood JA; Stevenson LW; Desai AS
    JACC Heart Fail; 2016 Jan; 4(1):1-8. PubMed ID: 26656139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF.
    DeVore AD; Hasselblad V; Mentz RJ; O'Connor CM; Armstrong PW; McMurray JJ; Ezekowitz JA; Tang WH; Starling RC; Voors AA; Califf RM; Hernandez AF
    Eur J Heart Fail; 2015 Mar; 17(3):340-6. PubMed ID: 25619549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis.
    Bradley SM; Levy WC; Veenstra DL
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):566-73. PubMed ID: 20031894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure.
    Ryder M; Murphy NF; McCaffrey D; O'Loughlin C; Ledwidge M; McDonald K
    Eur J Heart Fail; 2008 Mar; 10(3):267-72. PubMed ID: 18308632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs.
    Skrepnek GH; Abarca J; Malone DC; Armstrong EP; Shirazi FM; Woosley RL
    Ann Pharmacother; 2005 Nov; 39(11):1785-91. PubMed ID: 16219900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials.
    Wu MY; Chang NC; Su CL; Hsu YH; Chen TW; Lin YF; Wu CH; Tam KW
    J Crit Care; 2014 Feb; 29(1):2-9. PubMed ID: 24331943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD.
    Costanzo MR; Saltzberg MT; Jessup M; Teerlink JR; Sobotka PA;
    J Card Fail; 2010 Apr; 16(4):277-84. PubMed ID: 20350693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States.
    Greene SJ; Triana TS; Ionescu-Ittu R; Burne RM; Guérin A; Borentain M; Kessler PD; Tugcu A; DeSouza MM; Felker GM; Chen L
    JACC Heart Fail; 2020 Nov; 8(11):943-953. PubMed ID: 32800512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy.
    Cox ZL; Lenihan DJ
    J Card Fail; 2014 Aug; 20(8):611-22. PubMed ID: 24879974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction.
    Coiro S; Girerd N; McMurray JJV; Pitt B; Swedberg K; van Veldhuisen DJ; Lamiral Z; Rossignol P; Zannad F
    Clin Res Cardiol; 2021 Aug; 110(8):1308-1320. PubMed ID: 33956209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure.
    Testani JM; Hanberg JS; Cheng S; Rao V; Onyebeke C; Laur O; Kula A; Chen M; Wilson FP; Darlington A; Bellumkonda L; Jacoby D; Tang WH; Parikh CR
    Circ Heart Fail; 2016 Jan; 9(1):e002370. PubMed ID: 26721915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambulatory intravenous furosemide for decompensated heart failure: safe, feasible, and effective.
    Ahmed FZ; Taylor JK; John AV; Khan MA; Zaidi AM; Mamas MA; Motwani M; Cunnington C
    ESC Heart Fail; 2021 Oct; 8(5):3906-3916. PubMed ID: 34382749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of metolazone versus chlorothiazide in acute decompensated heart failure with diuretic resistance.
    Moranville MP; Choi S; Hogg J; Anderson AS; Rich JD
    Cardiovasc Ther; 2015 Apr; 33(2):42-9. PubMed ID: 25712736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF.
    Kittipibul V; Mentz RJ; Clare RM; Wojdyla DM; Anstrom KJ; Eisenstein EL; Ambrosy AP; Goyal P; Skopicki HA; Ketema F; Kim DY; Desvigne-Nickens P; Pitt B; Velazquez EJ; Greene SJ
    Eur J Heart Fail; 2024 Jul; 26(7):1518-1523. PubMed ID: 38745502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of combination diuretic therapy with oral hydrochlorothiazide or intravenous chlorothiazide in patients receiving intravenous furosemide therapy for the treatment of heart failure.
    Kissling KT; Pickworth KK
    Pharmacotherapy; 2014 Aug; 34(8):882-7. PubMed ID: 24990816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
    Mecklai A; Subačius H; Konstam MA; Gheorghiade M; Butler J; Ambrosy AP; Katz SD
    JACC Heart Fail; 2016 Jul; 4(7):580-588. PubMed ID: 27039131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.
    Caro JJ; Migliaccio-Walle K; O'Brien JA; Nova W; Kim J; Hauch O; Hillson E; Wedel H; Hjalmarson A; Gottlieb S; Deedwania PC; Wikstrand J;
    J Card Fail; 2005 Dec; 11(9):647-56. PubMed ID: 16360958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observation of Patients Transitioned to an Oral Loop Diuretic Before Discharge and Risk of Readmission for Acute Decompensated Heart Failure.
    Laliberte B; Reed BN; Devabhakthuni S; Watson K; Ivaturi V; Liu T; Gottlieb SS
    J Card Fail; 2017 Oct; 23(10):746-752. PubMed ID: 28688888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.